U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, by Drugs (Lenalidomide, Decitabine, Azacitidine, Luspatercept, and Phase 3 Drugs), by Route of Administration (Injection and Oral), by Distribution Channel (Hospital Pharmacies, Reta

U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, by Drugs (Lenalidomide, Decitabine, Azacitidine, Luspatercept, and Phase 3 Drugs), by Route of Administration (Injection and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Country/Region (U.S., Europe, and China) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

In myelodysplastic syndrome (MDS), some of the blood forming cells in bone marrow become abnormal and have problems in forming new and mature blood cells. The immature blood cells called as blasts get stored in the bone marrow and blood, and obstruct the natural function of the hematological system, which results in depletion of healthy red blood cells, platelets, and white blood cells. It is usually observed in geriatric population and more often in older men compared to women. For instance, according to the American Society of Clinical Oncology (ASCO), age plays an important role in the occurrence of myelodysplastic syndrome, as most of the people diagnosed with the disease are of age 65 and older.
Moreover, increasing possibility of MDS to further progress into rapidly growing cancer of bone marrow cells called acute myeloid leukemia (AML), leads to increasing efforts by key players develop highly effective therapies for MDS treatment. Furthermore, rising awareness about MDS and its symptoms with advanced methods and techniques for early diagnosis and treatment for various forms of the MDS is expected to drive the market growth over the forecast period. Increased understanding of the pathology of the syndrome is directing the research towards developing more specialized and symptom based treatments with effective costs, so that MDS patients can avail these benefits.
Market Dynamics
The increasing prevalence of MDS is expected to drive the demand of drugs used for the treatment of MDS, thereby expected to drive the U.S., Europe, and China myelodysplastic syndrome treatment market growth over the forecast period. Incidence rate for myelodysplastic syndrome has witnessed an increase in the last few years as the average population is ageing every consecutive year. For instance, according to the American Cancer Society report 2018, over 10,000 new cases of MDS occur in the U.S. every year, which is expected to boost the market growth.
Key features of the study:
This report provides in-depth analysis of the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and Strategies
Key companies covered as a part of this study include Bristol Myers Squibb, Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Limited, Cipla Limited, Acceleron Pharma, Inc., Onconova Therapeutics, Inc., Aprea Therapeutics, Geron, Fibrogen, Inc., Jazz Pharmaceuticals, AbbVie Inc., Lixte Biotechnology Holdings, Inc., Gilead Sciences, CrystalGenomics, Inc., ALX Oncology Inc., and Keros Therapeutics.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market
Detailed Segmentation:
U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Drugs:
Lenalidomide
Decitabine
Azacitidine
Luspatercept
Phase 3 Drugs
U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Route of Administration:
Injection
Oral
U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Country/Region:
U.S.
By Drugs
Lenalidomide
Decitabine
Azacitidine
Luspatercept
Phase 3 Drugs
By Route of Administration
Injection
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Drugs
Lenalidomide
Decitabine
Azacitidine
Luspatercept
Phase 3 Drugs
By Route of Administration
Injection
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
U.K.
By Drugs
Lenalidomide
Decitabine
Azacitidine
Luspatercept
Phase 3 Drugs
By Route of Administration
Injection
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Germany
By Drugs
Lenalidomide
Decitabine
Azacitidine
Luspatercept
Phase 3 Drugs
By Route of Administration
Injection
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Italy
By Drugs
Lenalidomide
Decitabine
Azacitidine
Luspatercept
Phase 3 Drugs
By Route of Administration
Injection
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
France
By Drugs
Lenalidomide
Decitabine
Azacitidine
Luspatercept
Phase 3 Drugs
By Route of Administration
Injection
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Spain
By Drugs
Lenalidomide
Decitabine
Azacitidine
Luspatercept
Phase 3 Drugs
By Route of Administration
Injection
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Russia
By Drugs
Lenalidomide
Decitabine
Azacitidine
Luspatercept
Phase 3 Drugs
By Route of Administration
Injection
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Rest of Europe
By Drugs
Lenalidomide
Decitabine
Azacitidine
Luspatercept
Phase 3 Drugs
By Route of Administration
Injection
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
China
By Drugs
Lenalidomide
Decitabine
Azacitidine
Luspatercept
Phase 3 Drugs
By Route of Administration
Injection
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Bristol Myers Squibb*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Otsuka Pharmaceutical Co., Ltd.
Teva Pharmaceutical Industries Ltd.
Mylan N.V.
Dr. Reddy's Laboratories Ltd.
Sun Pharmaceutical Industries Limited
Cipla Limited
Acceleron Pharma, Inc.
Onconova Therapeutics, Inc.
Aprea Therapeutics
Geron
Fibrogen, Inc.
Jazz Pharmaceuticals
AbbVie Inc.
Lixte Biotechnology Holdings, Inc.
Gilead Sciences
CrystalGenomics, Inc.
ALX Oncology Inc.
Keros Therapeutics.
“*” marked represents similar segmentation in other categories in the respective section.